Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long‐term goal of developing immunological criteria for managing IM therapy in CML patients, we compared the immunophenoty...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Mizuguchi, Junichiro, Tauchi, Tetsuzo, Kimura, Yukihiko, Inokuchi, Koiti, Ohyashiki, Junko H., Ohyashiki, Kazuma
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656535/
https://ncbi.nlm.nih.gov/pubmed/23758044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12216
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados